Your browser doesn't support javascript.
loading
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
Nastoupil, Loretta J; McLaughlin, Peter; Feng, Lei; Neelapu, Sattva S; Samaniego, Felipe; Hagemeister, Fredrick B; Ayala, Ana; Romaguera, Jorge E; Goy, Andre H; Neal, Eleanor; Wang, Michael; Fayad, Luis; Fanale, Michelle A; Oki, Yasuhiro; Westin, Jason R; Rodriguez, Maria A; Cabanillas, Fernando; Fowler, Nathan H.
  • Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • McLaughlin P; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Feng L; Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Samaniego F; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Hagemeister FB; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Ayala A; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Romaguera JE; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Goy AH; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Neal E; John Theurer Cancer Center, Hackensack, NJ, USA.
  • Wang M; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Fayad L; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Fanale MA; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Oki Y; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Westin JR; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Rodriguez MA; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Cabanillas F; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  • Fowler NH; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Br J Haematol ; 177(2): 263-270, 2017 04.
Article en En | MEDLINE | ID: mdl-28340281
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Interferones Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Interferones Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article